CIC
KRON

Cornercap Investment Counsel’s Kronos Bio KRON Stock Holding History

Cornercap Investment Counsel’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-40,208
Closed -$49.9K – 599
2024
Q2 		$49.9K Sell
40,208
-1,143
-3% -$1.16K 0.01% 582
2024
Q1 		$53.8K Hold
41,351
– – 0.01% 587
2023
Q4 		$51.7K Hold
41,351
– – 0.01% 563
2023
Q3 		$53.8K Buy
41,351
+563
+1% +$910 0.01% 543
2023
Q2 		$70.2K Buy
40,788
+6,481
+19% +$10.3K 0.01% 546
2023
Q1 		$50.1K Buy
34,307
+5,030
+17% +$9.64K 0.01% 542
2022
Q4 		$47.4K Hold
29,277
– – 0.01% 542
2022
Q3 		$98K Hold
29,277
– – 0.02% 527
2022
Q2 		$107K Buy
+29,277
New +$133K 0.02% 529

Other funds holding KRON

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.65B AUM 16.42% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cornercap Investment Counsel's KRON Position: Q3 2024 in Review

Cornercap Investment Counsel sold out of Kronos Bio (KRON) in Q3 2024, closing a stake of 40,208 shares — an estimated $49.9K sold.

Cornercap Investment Counsel first reported a position in KRON in Q2 2022 and held it in 9 quarters. The position peaked at $107K in Q2 2022. 53 funds tracked by Wall St. Rank hold KRON as of Q3 2024.

  • Cornercap Investment Counsel reported no remaining Kronos Bio position as of Q3 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 40,208 Kronos Bio shares in Q3 2024, an estimated $49.9K.
  • Cornercap Investment Counsel first reported a position in Kronos Bio in Q2 2022 and held it in 9 quarters.
  • Cornercap Investment Counsel's Kronos Bio position peaked at $107K in Q2 2022.
  • 53 funds tracked by Wall St. Rank held Kronos Bio as of Q3 2024.

Based on Cornercap Investment Counsel's 13F filing for Q3 2024, filed 6 Nov 2024.